Fusion Bridge Events

FusionBridge Events

FusionBridge Events


Itwas necessary to collect tumor cells from patients who had not beentreated by chemotherapy or radiation since this would help to knowhow such patients would react. The cells had to be collected so thatthey could be used for the purposes of culturing. Collection of thetumor cells was also done in order to ensure that the identificationof chromosomes took place with a lot of ease. With the collection ofthe tumor cells, the researchers could easily identify the telomericassociation, dicentric chromosome, as well as ring chromosome(Gisselssonet al, 2000).


Researcherslooked for mutations in p53 in order to determine the BFB instabilityin the tumor cells. The evaluation of the mutations was alsoinstrumental in determining whether the tumor cells had any genomicinstability, and researching whether there was overexpression of MDM2(Gisselssonet al, 2000).If I was the one conducting the study, I would not have checked forany additional genes as I believe that the genes checked aresufficient for the study.


Theresults differed between borderlineand low tumors vs. the highly malignant tumors this is because thetumors that can be referred as highly malignant has karyotypes thatwere more complex than those found in low tumors. In addition, thering chromosomes tend to be of varied shapes, sizes, and structure inlow malignant tumors while the chromosome complement is unstable inhighly malignant tumors (Gisselsson et al, 2000).


Thecells were irradiated so as to prevent TA-GVHD (TransfusionAssociated Graft-Versus Host Disease). This process is done throughgamma radiation whereby the cellular products of the blood areirradiated. From the results, researchers can deduce that there is aneed to change the culture medium upon irradiation (Gisselsson et al,2000).


Fromthe paper, cellular processes determine genomic instability, which isa common occurrence in types of tumors.


Gisselsson,D. et al. (2000). Chromosomal breakage-fusion-bridge events causegenetic intratumor heterogeneity. PNAS97,5357-5362.